MetaADEDB 2.0 @ LMMD
Raltegravir Potassium
(IFUKBHBISRAZTF-UHFFFAOYSA-M)
Structure
SMILES
Fc1ccc(cc1)CNC(=O)c1nc(n(c(=O)c1[O-])C)C(NC(=O)c1nnc(o1)C)(C)C.[K+]
Molecular Formula:
C20H20FKN6O5
Molecular Weight:
482.507
Log P:
2.1315
Hydrogen Bond Acceptor:
11
Hydrogen Bond Donor:
2
TPSA:
155.07
CAS Number(s):
871038-72-1
Synonym(s)
1.
Raltegravir Potassium
2.
Isentress
3.
MK 0518
4.
MK-0518
5.
MK0518
6.
Raltegravir
7.
0518, MK
8.
Potassium, Raltegravir
External Link(s)
MeSHD000068898
PubChem Compound23668479
135800706
CHEMBLCHEMBL518520
KEGGdr:D07133
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Pathogen resistanceFAERS: 5US FAERS
2Adverse eventFAERS: 2US FAERS
3HepatotoxicityFAERS: 2US FAERS
4Amylase increasedFAERS: 1US FAERS
5Blood creatine increasedFAERS: 1US FAERS
6Blood creatine phosphokinase increasedFAERS: 1US FAERS
7Congenital HydrocephalusFAERS: 1US FAERS
8DeafnessFAERS: 1US FAERS
9DementiaFAERS: 1US FAERS
10Drug dose omissionFAERS: 1US FAERS
11Drug exposure during pregnancyFAERS: 1US FAERS
12Drug ineffectiveFAERS: 1US FAERS
13Drug resistanceFAERS: 1US FAERS
14Ectopic kidneyFAERS: 1US FAERS
15Lipase increasedFAERS: 1US FAERS
16Lower respiratory tract infectionFAERS: 1US FAERS
17LymphomaFAERS: 1US FAERS
18MyalgiaFAERS: 1US FAERS
19MyositisFAERS: 1US FAERS
20PneumoniaFAERS: 1US FAERS
21PresyncopeFAERS: 1US FAERS
22Product use in unapproved indicationFAERS: 1US FAERS
23Product use issueFAERS: 1US FAERS
24RhabdomyolysisFAERS: 1US FAERS
25Stevens-Johnson SyndromeFAERS: 125811541CTD
US FAERS
26TuberculosisFAERS: 1US FAERS
27treatment failureFAERS: 1US FAERS
28HIV Infections21128663
22371894
CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120240

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.